



PRIOR AUTHORIZATION POLICY

POLICY: Hyperhidrosis – Qbrexza Prior Authorization Policy

- Qbrexza® (glycopyrronium cloth 2.4% for topical use – Journey Medical)

REVIEW DATE: 05/14/2025

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Qbrexza, a topical anticholinergic, is indicated for the treatment of **primary axillary** (i.e., underarm) **hyperhidrosis** in patients ≥ 9 years of age.¹

Qbrexza is applied topically using a single cloth once every 24 hours to clean dry skin on both of the underarm areas only (1 cloth per day); it is not intended for use on other body areas.

Guidelines

There are currently no guidelines for the treatment of hyperhidrosis published by a professional society. However, the International Hyperhidrosis Society, an independent, non-profit organization, provides an algorithm for the treatment of axillary hyperhidrosis (updated 2025).² Topical antiperspirant therapy (aluminum and zirconium salts) is considered first line treatment for primary axillary

hyperhidrosis. Qbrexza, Sofdra™ (sofipironium 12.45% topical gel) and botulinum toxin A injections are recommended as second line treatment options. It is noted that typically aluminum chloride hexahydrate 20% topical solution is the most commonly prescribed agent.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Qbrexza. All approvals are provided for the duration noted below.

- **Qbrexza® (glycopyrronium cloth 2.4% for topical use – Journey Medical)**

is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

- 1. Hyperhidrosis, Primary Axillary.** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):
 - A)** Patient is ≥ 9 years of age; AND
 - B)** Hyperhidrosis is significantly interfering with the ability to perform age-appropriate activities of daily living; AND
 - C)** The prescriber has excluded secondary causes of hyperhidrosis; AND
 - D)** Patient meets ONE of the following (i or ii):
 - i.** Patient has tried one prescription aluminum chloride-containing topical antiperspirant for at least 4 weeks and experienced inadequate efficacy; OR
Note: Examples of prescription aluminum chloride-containing topical antiperspirants include aluminum chloride 20% topical solution (Drysol, generics).
 - ii.** According to the prescriber, the patient has experienced significant intolerance with an aluminum-containing topical antiperspirant.

CONDITIONS NOT COVERED

- **Qbrexza® (glycopyrronium cloth 2.4% for topical use – Journey Medical)**

is(are) considered not medically necessary for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Hyperhidrosis, other than Primary Axillary.** Qbrexza is not intended for application to areas other than the axillae.¹

- 2. Concurrent Use with Sofdra (sofpironium 12.45% topical gel).** The safety and efficacy of concurrent use of Qbrexza and Sofdra have not been established.

REFERENCES

1. Qbrexza™ cloth [prescribing information]. Scottsdale, AZ: Journey Medical; December 2023.
2. International Hyperhidrosis Society. Primary axillary hyperhidrosis treatment algorithm. Updated February 2025. Available at: <https://sweathelp.org/treatments-hcp/clinical-guidelines/primary-focal-hyperhidrosis/primary-focal-axillary.html>. Accessed on May 8, 2025.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	12/06/2023
Early Annual Revision	A note was added to the criteria to provide examples of prescription aluminum chloride-containing topical antiperspirants.	05/01/2024
Update	The title of the policy was updated from "Qbrexza" to "Hyperhidrosis – Qbrexza" Prior Authorization.	06/28/2024
Selected Revision	Conditions Not Covered: Concurrent use of Qbrexza with Sofdra (sofpironium 12.45% topical gel) was added to the Policy.	07/17/2024
Annual Revision	No criteria changes.	05/14/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group.© 2025 The Cigna Group.